bioRxiv · 10.1101/2024.08.08.606885
A pan-variant miniprotein inhibitor protects against SARS-CoV-2 variants
Abstract
The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised neutralizing antibody responses elicited by prior infection or vaccination and abolished the utility of most monoclonal antibody therapeutics. We previously described a computationally-designed, homotrimeric miniprotein inhibitor, designated TRI2-2, that protects mice against pre-Omicron SARS-CoV-2 variants. Here, we show that TRI2-2 exhibits pan neutralization of variants that evolved during the 4.5 years since the emergence of SARS-CoV-2 and protects mice against BQ.1.1, XBB.1.5 and BA.2.86 challenge when administered post-exposure by an intranasal route. The resistance of TRI2-2 to viral escape and its direct delivery to the upper airways rationalize a path toward clinical advancement.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lee, J., Case, J. B., Ravichandran, R., Asarnow, D., Tortorici, M. A., Brown, J. T., Sanapala, S., Carter, L., Baker, D., Diamond, M. S., Veesler, D.. 2024-08-10. A pan-variant miniprotein inhibitor protects against SARS-CoV-2 variants. https://doi.org/10.1101/2024.08.08.606885
Cite the original work for its findings. Save a collection to share your selection of sources.